Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riociguat PK Interaction with HIV Antiretrovirals
NCT02556268Phase 1Completed
- Sponsor
- Bayer
- Start
- Feb 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of riociguat in pulmonary hypertension (PH) (5 arms), sponsored by Bayer. Primary endpoints: Area Under the Curve at 48 hours, Maximum Plasma Concentration at 48 hours and 2 more. Started Feb 2016; status: completed.
02
Drugs
riociguat
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT02556268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02556268.